Therefore, immune checkpoint inhibitors (ICIs) can be used to treat BCG non-responsive bladder cancer patients, but the overall response rate of bladder cancer patients to PD-L1/PD-1 blocking drugs is about 20-30%. This evidence concerns the gene CD274 and urinary bladder carcinoma.